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ABSTRACT
In the Western world, calcified aortic valve stenosis is the most common form of valvular heart disease, affecting up to 3% of adults over the age of 
75 years. It is a gradually progressive disease, characterized by a long asymptomatic phase that may last for several decades, followed by a short 
symptomatic phase associated with severe restriction of the valve orifice. Investigations on treatments for aortic valve stenosis are still in progress. 
Thus, it is believed that calcification of aortic valve stenosis is similar to the process of atherosclerosis that occurs in coronary artery disease. Recent 
studies have suggested that cholesterol lowering through the use of statins may have a salutary effect on the progression of aortic valve stenosis.
RESUMO
No mundo ocidental, a estenose da valva aórtica calcificada é a forma mais comum de doença cardíaca valvar, afetando até 3% dos adultos com 
idade acima de 75 anos. É uma doença gradual e progressiva, caracterizada por uma longa fase assintomática, podendo durar várias décadas, 
seguida de uma curta fase sintomática associada à restrição grave do orifício da valvar. A investigação sobre o tratamento da estenose da valva 
aórtica ainda está em curso. Desta forma, acredita-se que a calcificação da estenose da valva aórtica seja semelhante ao processo de aterosclerose 
que ocorre na doença arterial coronariana. Estudos recentes têm sugerido que a redução do colesterol pelo do uso das estatinas pode ter um efeito 
salutar sobre a progressão da estenose da valva aórtica.
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INTRODUCTION
Aortic valve stenosis in adults is characterized by degenerative 
changes to the valve cusps that hinder proper emptying of the left 
ventricle and promote the development of ventricular hypertro-
phy. The main causes of valve disease are congenital, rheumatic and 
degenerative (i.e. age-related). Currently, the main types of aortic 
valve stenosis are bicuspid and tricuspid calcification.1 
Aortic calcification often presents greater development in pa-
tients with bicuspid aortic valves, a condition that affects 1-2% of 
the population and predominates in males.1  When this situation 
develops, it happens relatively early, at the age of 50-60 years.1 
However, the most frequent form of presentation, tricuspid calci-
fied aortic stenosis, occurs in 2-7% of adults over 65 years of age.1 
In the latter patients, as the obstruction gradually develops, the left 
ventricle adapts to pressure overload through a hypertrophy proc-
ess that results in increased wall thickness, while the chamber vol-
ume is maintained. The development of concentric hypertrophy 
appears to be an appropriate and beneficial adaptation to compen-
sate for high intracavitary pressures. However, if this process is in-
sufficient, the ejection capacity becomes reduced and left ventricu-
lar systolic dysfunction occurs. As a consequence of ventricular hy-
pertrophy and decreased compliance of the chamber, there is also 
an increase in diastolic pressure without dilatation of the chamber. 
Thus, this increased pressure is also a reflection of the left ventricu-
lar diastolic dysfunction.1
This situation of a hypertrophied heart may diminish the coro-
nary blood flow per gram of muscle and also exposes the limited 
coronary reserve. Thus, under conditions of exercise or tachycardia, 
maldistribution of blood flow and coronary subendocardial ische-
mia may occur. Concomitantly with this process, myocardial fibro-
sis is another early morphological alteration in patients with aor-
tic valve stenosis, and this provides substrates for arrhythmias and 
gives rise to progression of heart failure and sudden death.1 
The historical concept of aortic valve calcification was that it 
was a passive process, with serum calcium associated with the sur-
face of the valve leaflet, thus forming a nodule. However, epidemi-
ological studies, histopathological studies and recent experimental 
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evidence have indicated that calcification of the aortic valve is an ac-
tive biological process rather than a passive process within the leaflet, 
thus causing regulated bone formation.2
Similarities in risk factors strongly suggest that there are simi-
larities in the underlying process of development and progression 
between calcific aortic valve stenosis and coronary atherosclerosis. 
The risk factors shared by these two disorders include hypertension, 
dyslipidemia (low levels of high-density lipoprotein; LDL), male 
gender, smoking and diabetes mellitus. Important histopathologi-
cal evidence that calcific aortic valve stenosis develops in the same 
way as seen in atherosclerosis was reported by O’Brien et al.,3 who 
found that apolipoproteins B and E were present in early lesions 
and advanced aortic valve stenosis, but not in the region of nor-
mal valves, and found the same pattern of lipoproteins in coronary 
atherosclerosis.2,3
In the Western world, calcified aortic valve stenosis is the most 
common form of valvular heart disease, affecting 3-5% of adults 
over 75 years of age. It is a gradually progressive disease, character-
ized by a long asymptomatic phase lasting several decades with a risk 
of death of less than 1% per year, followed by a shorter symptomat-
ic phase that is associated with severe restriction of the valve orifice. 
The progression rate varies, but the average reduction in the valve 
orifice is 0.1 cm2 each year.4
In degenerative calcific aortic valve stenosis, the progression be-
gins at the base of the leaflets and heads towards the hole. All three 
cusps are usually affected, but one may be more dominant. In calci-
fication, early progression starts in the middle raphe. In rheumatic 
disease, progression is greatest in the commissures. Significant calci-
fication is associated with relatively rapid progression.4
The clinical criteria involved in diagnosing calcified aortic valve 
stenosis include the medical history and physical examination find-
ings. The main clinical manifestations are angina pectoris, stroke, 
dyspnea on exertion and, ultimately, heart failure. In physical exam-
inations, the arterial pulse may be found to be small and sustained, 
the cardiac pulse may be shifted inferiorly and laterally by left heart 
failure, and the systolic thrill may be palpable in the second intercos-
tal space bilaterally. Finally, cardiac auscultation may reveal a single 
second sound and a systolic murmur with a late peak, heard more 
clearly at the base of the heart. All the physical examination find-
ings, including delayed ascending carotid pulse, loud and prolonged 
systolic murmur and single second heart sound, have been found to 
correlate with stenosis.5
After the onset of these symptoms, the mean survival is 4.5 years 
with angina, 2.6 years with dizziness on exertion and one year with 
the presence of left heart failure limitation. These symptoms occur 
primarily through low cardiac output and decreased coronary flow. 
The survival in the advanced stage of the disease is short: 20% over 
a three-year period for patients with major left ventricle impair-
ment in functional class III or IV of the New York Heart Associa-
tion (NYHA). The mortality rate is non-linear and approximately 
10% of patients die during the first six months after the onset of 
symptoms.4
To evaluate disease progression, all patients should be tested us-
ing Doppler echocardiography, which is the gold standard test for 
diagnosing the disease. Patients with moderate aortic stenosis should 
undergo this test once a year and those with severe symptoms that 
are close to indications for surgery should undergo Doppler echocar-
diography every six months.4 A transthoracic echocardiography is 
useful for detecting valvular calcifications, designing leaflets, deter-
mining the severity of stenosis (through viewing the hole) and en-
abling calculations on the pressure gradient that is formed between 
the left ventricle and aorta.
The limit that is considered normal for aortic valve opening is 
1.6 - 2.6 cm.4 The actual size of the aortic valve orifice is not usual-
ly visible by means otransthoracic echocardiography. Thus, transoe-
sophageal echocardiography may also be useful for calculating direct 
measurements on the valve orifice in patients with aortic valve steno-
sis. However, from a practical standpoint, it is unnecessary to deter-
mine the valve area. The echocardiographic criterion for considering 
that the aortic valve stenosis is clinically significant is the presence 
of a gradient greater than 50 mmHg,4,5 which corresponds to a peak 
aortic jet velocity of 3.5 m/s.6
Stress tests may also be useful for apparently asymptomatic pa-
tients, in order to detect hidden symptoms, limited ability to ex-
ercise and abnormal blood pressure responses. Tension on exercis-
ing must be absolutely avoided for symptomatic patients.5 Such pa-
tients, with severe disease, are candidates for surgery, since clinical 
therapy has little to offer. However, clinical treatment may be neces-
sary for patients who are considered inoperable. The drugs that may 
apply in these cases are digitalis, angiotensin-converting enzyme in-
hibitors and diuretics, and beta-blockers should be avoided because 
they decrease myocardial function.5
Currently, aortic valve stenosis is the main indication for valve 
replacement in North America and Europe. In the United States, 
16,330 single procedures and 14,976 procedures associated with 
myocardial revascularization were reported by the Society of Tho-
racic Surgeons in 2006.2 Thus, cardiac surgery with extracorporeal 
circulation and aortic valve replacement with mechanical or biologi-
cal prostheses has been the procedure of choice in severe cases. Con-
ventional surgery provides symptomatic improvement and increased 
survival for most patients with low surgical risk.7 However, in pa-
tients with associated diseases, very elderly patients, cases of reoper-
ation and cases of severe ventricular dysfunction, the mortality rate 
can reach 50%.8,9
Recently, the concept of degenerative valve disease has been re-
placed by evidence of an active inflammatory process that in many 
ways is related to atherosclerosis (elevation of LDL cholesterol and 
its oxidation by macrophages) and coronary artery disease.10 There-
fore, the effect of therapy to reduce lipid levels in relation to pro-
gression of aortic valve calcification has begun to be tested. Several 
prospective studies have suggested that statins may provide benefits 
for these patients.11,12
In 1976, the Japanese scientist Akira Endo identified a fungal 
metabolite that blocks cholesterol synthesis by inhibiting the en-
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zyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase. This resulted in the first “statin” agent, mevastatin.13 Sta-
tins are substances capable of decreasing the intracellular synthesis 
of cholesterol by competing with HMG-CoA reductase, thereby par-
tially inhibiting its action. This partial inhibition also ensures for-
mation of the cholesterol necessary for balancing the cell membrane 
and synthesizing steroid hormones and vitamin D.14
Absorption and excretion of statins occur in the gut, and their 
metabolization occurs in the liver. All statins are metabolized to a 
greater or lesser degree in cytochrome P 450, through different en-
zyme systems. In addition to reducing intracellular cholesterol syn-
thesis, statins increase LDL receptors, particularly in the liver, thus 
allowing greater clearance of these particles and consequently de-
creasing their plasma levels.14
Additionally, statins interfere with the secretion of very low den-
sity lipoproteins (VLDL), which contributes towards reducing the 
LDL in circulation. Lower production of VLDL and higher capture 
of VLDL remnants are responsible for a decrease in triglycerides. St-
atins slightly reduce the levels of high-density lipoprotein (HDL), 
probably by decreasing the activity of protein-cholesterol ester trans-
fer and increasing the synthesis of apolipoprotein Al.14
In practice, at the usual doses, statins reduce LDL levels by 7% 
and triglycerides by 22-45%, and increase HDL levels by 5-10%. 
These changes differ for each drug and are dose-dependent. Doses 
should be checked after 15 days of use, and they stabilize after one 
month of treatment.14 
In addition to blocking this key enzyme involved in cholesterol 
synthesis, statins have several pleiotropic properties, including: in-
creased nitric oxide in cases of endothelial dysfunction, upregulation 
of the expression of endothelin-1, antioxidant effects, anti-inflam-
matory properties, stabilization of atherosclerotic plaques, anticoag-
ulant effects and inhibition of graft rejection after kidney and heart 
transplantation.13
Although the role of the pleiotropic effects of statins in cardio-
vascular prevention remains to be determined, statins have became 
one of the classes of drugs most commonly sold up to the present 
day, since their introduction to the market in 1986. Currently, the 
drugs available commercially in Brazil and the United States, in or-
der of release are: lovastatin, pravastatin, fluvastatin, atorvastatin, 
simvastatin and rosuvastatin.13,15
Since the introduction of statins, many clinical trials have dem-
onstrated the importance of statins in primary and secondary pre-
vention of cardiovascular disease, especially coronary artery disease. 
The Myocardial Ischaemia Reduction with Aggressive Cholesterol 
Lowering Study (MIRACL Trial), for example, was a randomized, 
double-blind, controlled trial comparing atorvastatin with placebo 
among patients with an acute coronary syndrome event (unstable 
angina or acute myocardial infarction without ST elevation).16 
The primary endpoint of the MIRACL Trial16 was to determine 
whether treatment with atorvastatin at a dose of 80 mg/day, start-
ing within the first 24 to 96 hours would reduce mortality, nonfatal 
ischemic events, heart failure, recurrent symptoms of myocardial is-
chemia requiring hospitalization, and calcification. These outcomes 
occurred in 228 patients (14.8%) in the atorvastatin group and 269 
patients (17.4%) in the placebo group (relative risk, RR = 0.84; 95% 
confidence interval, CI: 0.70 to 1.0; P = 0.048).
The MIRACL Trial16 found that there were no significant differ-
ences in the risks of death, non-fatal acute myocardial infarction or 
cardiac arrest between the atorvastatin group and the placebo group, 
although the atorvastatin group had a lower risk of symptoms of re-
current ischemia with rehospitalization (6.2% versus 8.4%; RR = 
0.74; 95% CI: 0.57 to 0.95; P = 0.02). There was also no significant 
difference between the atorvastatin group and the placebo group 
with regard to secondary outcomes, including surgical or percutane-
ous myocardial revascularization, nonfatal stroke, heart failure and 
angina with rehospitalization, such that there were no signs of myo-
cardial ischemia or changes in lipid profile between the beginning 
and the end of the follow-up (RR = 1.01; 95% CI: 0.88 to 1.15; 
for any event). In the atorvastatin group, the plasma levels of LDL 
cholesterol decreased from 124 mg/dl to 72 mg/dl. Abnormal liver 
transaminase levels (three times above normal) were found more fre-
quently in the atorvastatin group than in the placebo group (2.5% 
versus 0.6%, P = 0.001). The conclusion from this study was that 
for patients with acute coronary syndrome, lipid-lowering therapy 
with atorvastatin at a dose of 80 mg/day reduced recurrent ischemic 
events during the first 16 weeks, especially the symptoms of recur-
rent ischemia with rehospitalization.16
Another very important study on primary prevention of cardio-
vascular events, with an impact on the world scientific community, 
was the Rosuvastatin to Prevent Vascular Events in Men and Women 
with Elevated C-Reactive Protein (Jupiter Trial).17 Since statins de-
crease the levels of high-sensitivity C-reactive protein (CRP) as well 
as cholesterol levels, this trial hypothesized that people with elevated 
high-sensitivity CRP levels but without hyperlipidemia might ben-
efit from statin treatment, because elevated CRP levels predispose 
towards cardiovascular events.
This randomized double-blind controlled trial17 selected 17,802 
healthy men and women with LDL cholesterol levels of less than 130 
mg/dl (3.4 mmol/l) and high-sensitivity CRP levels of 2.0 mg/l or 
higher, who were given rosuvastatin 20 mg/day or placebo. The sub-
jects were followed up to monitor for occurrences of the combined 
primary outcomes of myocardial infarction, stroke, arterial revascu-
larization, hospitalization due to unstable angina or death from car-
diovascular causes. The trial was stopped after a mean follow-up of 
1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol 
levels by 50% and high-sensitivity CRP levels by 37%. 
The primary outcome rates were 0.77 and 1.36 per 100 person-
years of follow-up in the rosuvastatin and placebo groups, respective-
ly (hazard ratio [HR] for rosuvastatin, 0.56; 95% CI, 0.46 to 0.69; P 
< 0.00001), with corresponding rates of 0.17 and 0.37 for myocar-
dial infarction (HR, 0.46; 95% CI, 0.30 to 0.70; P = 0.0002); 0.18 
and 0.34 for stroke (HR, 0.52; 95% CI, 0.34 to 0.79; P = 0.002); 
0.41 and 0.77 for revascularization or unstable angina (HR, 0.53; 
95% CI, 0.40 to 0.70; P < 0.00001); 0.45 and 0.85 for the com-
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bined outcome of myocardial infarction, stroke or death from car-
diovascular causes (HR, 0.53; 95% CI, 0.40 to 0.69; P < 0.00001); 
and 1.00 and 1.25 for death from any cause (HR, 0.80; 95% CI, 
0.67 to 0.97; P = 0.02). Thus, in this trial on apparently healthy in-
dividuals without hyperlipidemia but with elevated high-sensitivity 
CRP levels, rosuvastatin significantly reduced the incidence of major 
cardiovascular events.17
Given the clinical association with hypercholesterolemia and 
coronary artery disease, and the histological similarities with ather-
oma, it has been suggested that statin therapy may halt the pro-
gression, or even induce regression of calcific aortic valve stenosis, 
through its mechanisms of action. Several retrospective observation-
al studies conducted a few years ago showed that statin therapy was 
associated with delayed disease progression and showed that the rate 
of change in aortic jet velocity went down by 0.30 m per second per 
year and that rate of change in valvular calcification went down by 
30%.18-23
Recently, new studies have appeared, with the same proposition 
of examining the relationship between statins and the progression 
of aortic valve stenosis. The TASS trial (Tyrolean Aortic Stenosis 
Study), for example, had a prospective, randomized, placebo-con-
trolled design and characterized the natural history, risk factors and 
possible modulation of calcified aortic valve stenosis through admin-
istration of atorvastatin 20 mg/day, versus placebo. However, this 
study did not show that treatment with atorvastatin was effective 
in relation to progression of calcific aortic stenosis through improv-
ing the pressure gradient between the aortic valve and left ventricle 
(RR = 1.02; 95% CI: 0.96 to 1.08; P = 0551).24
On the other hand, in the non-randomized, prospective, obser-
vational and open RAAVE study (Rosuvastatin in Endothelial Dys-
function in Aortic Valve), a change in the size of the aortic valve in 
the control group from -0.10 ± 0.09 cm2 per year was found, com-
pared with -0.05 ± 0.12 cm2 per year in the rosuvastatin group (P = 
0.041). Furthermore, the increase in peak velocity of the aortic valve 
was 0.24 ± 0.30 m/s/year in the control group, compared with 0.04 
± 0.38 m/s/year in the rosuvastatin group (P = 0.007). These data 
indicate that within this hypothesis, slowing of the progression of 
aortic disease was found through echocardiography.25
Given that there is no robust scientific evidence to change clin-
ical practice, patients with aortic valve stenosis are still being sub-
jected to invasive procedures such as exchange of the valve appa-
ratus. Patients often remain asymptomatic for long periods, while 
the disease becomes established through a constant inflammatory 
process.
Within this scenario, when diagnosed, patients are already at an 
advanced stage of the disease process, with significant valve narrow-
ing, deterioration of myocardial function and poor quality of life. 
Moreover, many patients are also exposed to chronic diseases such as 
diabetes mellitus, hypertension, dyslipidemia and smoking, which 
hinder the postoperative recovery if they have to undergo a surgi-
cal procedure. They may have to spend a long time in hospital, with 
burdensome costs for the health service.
Therefore, to allow new decisions to be made regarding clinical 
interventions such as the use of statins for treating aortic valve steno-
sis, it is important that evidence should be available from a systemat-
ic review of randomized controlled trials using the Cochrane meth-
odology. On this topic, no such review currently exists. Systematic 
reviews of the literature are studies that integrate the results from 
primary studies and provide a basis for rational decision-making.26
Systematic reviews make it possible to distinguish between ef-
fective and ineffective types of treatment, clarify controversies about 
treatments, determine the clinical decisions that need to be imple-
mented, and limit the chances of systematic and random errors in 
the analysis, thereby providing results with greater reliability.27-29
CONCLUSION
We believe that this review is important because of the impact 
that aortic valve stenosis has had in the Western world, especially 
among the elderly. Thus, a systematic review of all randomized con-
trolled trials identified and selected from the search strategy that ad-
dress the safety and effectiveness of treatment with hydroxy-methyl-
glutaryl-CoA reductase (statins) for patients with aortic valve steno-
sis is currently in progress at the Brazilian Cochrane Centre in con-
junction with the Heart Group of the Cochrane Collaboration based 
at the Department of Non-Communicable Disease Epidemiology, 
London School of Hygiene & Tropical Medicine, United Kingdom. 
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